FDA Approves OCREVUS — Genentech, Inc.

# FDA Approves Genentech's OCREVUS for Multiple Sclerosis Treatment Genentech announced FDA approval of OCREVUS (ocrelizumab), an intravenous monoclonal antibody therapy, positioning the company to capture significant market share in the multiple sclerosis treatment space and establishing a new standard of care for relapsing and primary progressive MS patients. The approval marks Genentech's entry into the lucrative MS market with a potentially blockbuster therapy, expected to generate substantial revenue while intensifying competition among existing MS drug manufacturers.